Pleomorphic lobular carcinoma of the breast with osteoclast-like giant cells: a case report and review of the literature

被引:12
作者
Pena-Jaimes, Lourdes [1 ]
Gonzalez-Garcia, Irene [1 ]
Eugenia Reguero-Callejas, Maria [1 ,4 ]
Pinilla-Pagnon, Ignacio [1 ]
Perez-Mies, Belen [1 ,4 ]
Albarran-Artahona, Victor [2 ]
Martinez-Janez, Noelia [2 ,4 ]
Manuel Rosa-Rosa, Juan [3 ,4 ]
Palacios, Jose [1 ,3 ,4 ,5 ]
机构
[1] Hosp Ramon & Cajal, Dept Pathol, Madrid, Spain
[2] Hosp Ramon & Cajal, Dept Oncol, Madrid, Spain
[3] Insituto Salud Carlos III, CIBER ONC, Madrid, Spain
[4] Inst Ramon & Cajal Invest Sanitaria, Madrid, Spain
[5] Univ Alcala de Henares, Madrid, Spain
基金
美国国家卫生研究院;
关键词
Pleomorphic carcinoma; Osteoclast-like giant cells; Breast cancer; Lobular carcinoma; INTERNATIONAL EXPERT CONSENSUS; PRIMARY THERAPY; DIGITAL PATHOLOGY; CANCER HIGHLIGHTS; PROGNOSTIC VALUE; KI-67; INDEX; KI67; PROLIFERATION; EXPRESSION; ANASTROZOLE;
D O I
10.1186/s13000-018-0744-6
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Breast carcinoma with osteoclast-like giant cells (OGCs) is infrequent, being most reported cased described as ductal invasive carcinomas. Invasive pleomorphic lobular carcinoma (PLC) is a distinct morphological variant of invasive lobular carcinoma characterized by higher nuclear atypia and pleomorphism than the classical type. In the best of our knowledge, a PLC with OGCs has not been previously reported. Case presentation: We report the case of a 72-year-old woman presenting with a pleomorphic tumor of the left breast with a dense infiltration by OGCs and T lymphocytes with a 10:1 predominance of CD8+ over CD4+ cells. The diagnosis of a lymphoid or mesenchymal neoplasia was excluded after demonstrating keratin expression by the neoplastic cells. The absence of E-cadherin expression and the morphological features were consistent with the diagnosis PLC with OGCs. In addition, we demonstrated the deleterious mutation C.del866C in CDH1gene, but no mutations in any of the other 33 genes analyzed by next generation sequencing. Conclusions: Breast carcinoma with stromal osteoclast-like giant cells is a very rare tumor, for that reason, the use of the cytologic features and growth patterns in combination with immunohistochemically studies is mandatory for a correct diagnosis of lobular carcinoma. In addition, further studies are necessary to clarify the influence of OGCs in the prognosis of these patients.
引用
收藏
页数:15
相关论文
共 39 条
  • [1] Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups
    Abubakar, Mustapha
    Orr, Nick
    Daley, Frances
    Coulson, Penny
    Ali, H. Raza
    Blows, Fiona
    Benitez, Javier
    Milne, Roger
    Brenner, Herman
    Stegmaier, Christa
    Mannermaa, Arto
    Chang-Claude, Jenny
    Rudolph, Anja
    Sinn, Peter
    Couch, Fergus J.
    Devilee, Peter
    Tollenaar, Rob A. E. M.
    Seynaeve, Caroline
    Figueroa, Jonine
    Sherman, Mark E.
    Lissowska, Jolanta
    Hewitt, Stephen
    Eccles, Diana
    Hooning, Maartje J.
    Hollestelle, Antoinette
    Martens, John W. M.
    van Deurzen, Carolien H. M.
    Bolla, Manjeet K.
    Wang, Qin
    Jones, Michael
    Schoemaker, Minouk
    Wesseling, Jelle
    van Leeuwen, Flora E.
    Van 't Veer, Laura
    Easton, Douglas
    Swerdlow, Anthony J.
    Dowsett, Mitch
    Pharoah, Paul D.
    Schmidt, Marjanka K.
    Garcia-Closas, Montserrat
    [J]. BREAST CANCER RESEARCH, 2016, 18
  • [2] Digital pathology: current status and future perspectives
    Al-Janabi, Shaimaa
    Huisman, Andre
    Van Diest, Paul J.
    [J]. HISTOPATHOLOGY, 2012, 61 (01) : 1 - 9
  • [3] American Cancer Society, 2015, Global Cancer Facts Figures, V3rd ed., P37
  • [4] Ayad E, 2016, VIRCHOWS ARCH, V469, pS191
  • [5] Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up
    Bustreo, Sara
    Osella-Abate, Simona
    Cassoni, Paola
    Donadio, Michela
    Airoldi, Mario
    Pedani, Fulvia
    Papotti, Mauro
    Sapino, Anna
    Castellano, Isabella
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 363 - 371
  • [6] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
    Cheang, Maggie C. U.
    Chia, Stephen K.
    Voduc, David
    Gao, Dongxia
    Leung, Samuel
    Snider, Jacqueline
    Watson, Mark
    Davies, Sherri
    Bernard, Philip S.
    Parker, Joel S.
    Perou, Charles M.
    Ellis, Matthew J.
    Nielsen, Torsten O.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10): : 736 - 750
  • [7] Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
    Coates, A. S.
    Winer, E. P.
    Goldhirsch, A.
    Gelber, R. D.
    Gnant, M.
    Piccart-Gebhart, M.
    Thuerlimann, B.
    Senn, H. -J.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (08) : 1533 - 1546
  • [8] Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists
    Dowsett, M
    Ebbs, SR
    Dixon, JM
    Skene, A
    Griffith, C
    Boeddinghaus, I
    Salter, J
    Detre, S
    Hills, M
    Ashley, S
    Francis, S
    Walsh, G
    Smith, IE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) : 2477 - 2492
  • [9] Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
    Dowsett, Mitch
    Nielsen, Torsten O.
    A'Hern, Roger
    Bartlett, John
    Coombes, R. Charles
    Cuzick, Jack
    Ellis, Matthew
    Henry, N. Lynn
    Hugh, Judith C.
    Lively, Tracy
    McShane, Lisa
    Paik, Soon
    Penault-Llorca, Frederique
    Prudkin, Ljudmila
    Regan, Meredith
    Salter, Janine
    Sotiriou, Christos
    Smith, Ian E.
    Viale, Giuseppe
    Zujewski, Jo Anne
    Hayes, Daniel F.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22): : 1656 - 1664
  • [10] Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
    Ellis, Matthew J.
    Suman, Vera J.
    Hoog, Jeremy
    Lin, Li
    Snider, Jacqueline
    Prat, Aleix
    Parker, Joel S.
    Luo, Jingqin
    DeSchryver, Katherine
    Allred, D. Craig
    Esserman, Laura J.
    Unzeitig, Gary W.
    Margenthaler, Julie
    Babiera, Gildy V.
    Marcom, P. Kelly
    Guenther, Joseph M.
    Watson, Mark A.
    Leitch, Marilyn
    Hunt, Kelly
    Olson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) : 2342 - 2349